Numerous prognostic factors in BC risk for relapse have been established, including tumor size, nodal status, hormone receptor status, and grade, but recognition and appreciation of these clinically distinct molecular subgroups may be helpful in predicting tumor behavior and guiding practice, with the awareness that the management of each patient must be considered in the context of that individual’s unique presentation. Here, NR4A1 is linked to neoplasm.